Drugs / BENDAMUSTINE DODECYL ESTER
BENDAMUSTINE DODECYL ESTER
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02548390 | Sep 2015 → Sep 2016 | cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BENDAMUSTINE DODECYL ESTER | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297425 ↗ |
| Known as | CEP-40125 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297425 ↗ |
| Known as | RXDX-107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02548390 ↗ |
| Modality | Small molecule | — CHEMBL4297425 ↗ |
| Route | Intravenous | “receive RXDX-107 intravenously” NCT02548390 ↗ |